eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | american trypanosomiasis |
| Symptom | C0018801|heart failure |
| Sentences | 22 |
| PubMedID- 20502520 | Nearly 60% of symptomatic congestive heart failure was due to chagas disease; mortality was also higher for infected than uninfected patients. |
| PubMedID- 21820551 | Treatment options for heart failure due to chagas disease are not different from standard therapy. |
| PubMedID- 23272265 | In human clinical studies of patients with end-stage heart failure due to chagas disease the administration of autologous bone marrow mononuclear cells did not improve cardiac function . |
| PubMedID- 20802940 | Evaluation of the six-minute walk test in patients with chronic heart failure associated with chagas' disease and systemic arterial hypertension. |
| PubMedID- 24984860 | Introduction: new therapeutic options are necessary for patients with chronic chagas disease, a leading cause of heart failure in latin american countries. |
| PubMedID- 21484040 | chagas disease was the cause of heart failure in 92 (20.4%) patients who had higher b type natriuretic peptide levels (1,978.38 vs. |
| PubMedID- 24627740 | chagas disease, a major cause of heart failure (hf) in latin america, affects approximately eight million people1 and represents a significant public health and socio-economic problem in these countries. |
| PubMedID- 20006935 | Accordingly, in this study we compare outcomes in chagas' disease with non-chagas'-disease-related advanced heart failure among patients on the waiting list for heart transplantation. |
| PubMedID- 20591516 | Conclusion: b-blockers are effective, not detrimental, and may improve survival in chagas' disease patients with chronic heart failure. |
| PubMedID- 22513344 | Conclusions: in heart failure patients with chagas disease, the heart failure survival score correlated well with the main prognostic functional test variables. |
| PubMedID- 23152267 | Despite the substantial burden to the healthcare system, there is uncertainty regarding the efficacy and safety of pharmacological interventions for treating heart failure in patients with chagas disease. |
| PubMedID- 23031286 | Conclusion: altogether our results demonstrate that heart failure in chagas' disease may occur due to electrical and mechanical remodeling of cardiac myocytes, and suggest that akt/pi3k/no axis could be an important pharmacological target to improve the disease outcome. |
| PubMedID- 23871619 | Cardiopulmonary exercise and 6-min walk tests as predictors of quality of life and long-term mortality among patients with heart failure due to chagas disease. |
| PubMedID- 20385875 | chagas' disease, the leading cause of heart failure in latin america, is caused by the kinetoplastid protozoan trypanosoma cruzi. |
| PubMedID- 25886035 | If untreated, chagas disease can lead to heart failure and death. |
| PubMedID- 22558095 | Luis fabrega” in santiago city in may of 2010. the patient came from el pantano community, one of our evaluated areas, and presented a heart failure compatible with chronic chagas disease and a positive serology for t. cruzi. |
| PubMedID- 26407508 | After a decade or more, 20% to 30% of people will experience chronic cardiovascular chagas disease with sequelae including heart failure, arrhythmias, and thromboembolism. |
| PubMedID- 22811738 | In situ expression of regulatory cytokines by heart inflammatory cells in chagas' disease patients with heart failure. |
| PubMedID- 22011801 | Conclusion: the prevalence of asymptomatic coronary artery disease in patients with severe heart failure due to chagas disease is low and among the risk factors for coronary heart disease, smoking was the most prevalent. |
| PubMedID- 24918914 | Our data suggest that patients with heart failure due to chagas disease and class iiiand iv heart failure submitted to transplantation of stem cells from bone marrow to themyocardium, showed no increase in the incidence of sustained ventricular tachycardia,but showed increase in nonsustained ventricular tachycardia between holter atrandomization and holter at 6 months in the study group, as well as increased vpbdensity in the study group. |
| PubMedID- 21359478 | Background: heart failure due to chagas' disease (hfcd) is a progressive inflammatory cardiomyopathy that affects millions of individuals in latin america. |
| PubMedID- 23787193 | Methods: we retrospectively analyzed the outcome of 54 chagas disease patients without heart failure and with left ventricular (lv) ejection fraction >45% whose tgf-beta1 serum values were determined between january 1998 and december 1999. |
Page: 1